B lymphocytes differentially influence acute and chronic allograft rejection in mice

Journal of Immunology

Volumn 186, Issue 4, 2011, Pages 2643-2654

  DiLillo, David J ^a   Griffiths, Robert ^a   Seshan, Surya V ^b   Magro, Cynthia M ^b   Ruiz, Phillip ^c   Coffman, Thomas M ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD19 ANTIBODY; CD20 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; GRAFT REJECTION; KIDNEY GRAFT REJECTION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SKIN GRAFT REJECTION; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD20; B-LYMPHOCYTE SUBSETS; CELL LINE, TUMOR; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; SKIN TRANSPLANTATION;

EID: 79951838633     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002983     Document Type: Article

References (65)

1. Linton, P. J., J. Harbertson, and L. M. Bradley. 2000. A critical role for B cells in the development of memory CD4 cells. J. Immunol. 165: 5558-5565.
2. Crawford, A., M. Macleod, T. Schumacher, L. Corlett, and D. Gray. 2006. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. 176: 3498-3506. (Pubitemid 43363997)
3. + T cell activation in mice. Proc. Natl. Acad. Sci. USA 104: 20878-20883.
4. + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184: 4006-4016.
5. O'Neill, S. K., Y. Cao, K. M. Hamel, P. D. Doodes, G. Hutas, and A. Finnegan. 2007. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J. Immunol. 179: 5109-5116.
6. Linton, P. J., B. Bautista, E. Biederman, E. S. Bradley, J. Harbertson, R. M. Kondrack, R. C. Padrick, and L. M. Bradley. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197: 875-883.
7. DiLillo, D. J., T. Matsushita, and T. F. Tedder. 2010. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. N. Y. Acad. Sci. 1183: 38-57.
8. + phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650.
9. Matsushita, T., K. Yanaba, J.-D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
10. Watanabe, R., N. Ishiura, H. Nakashima, Y. Kuwano, H. Okochi, K. Tamaki, S. Sato, T. F. Tedder, and M. Fujimoto. 2010. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J. Immunol. 184: 4801-4809.
11. Brändle, D., J. Joergensen, G. Zenke, K. Bürki, and R. P. Hof. 1998. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation 65: 1489-1493.
12. Alexander, D. Z., T. C. Pearson, R. Hendrix, S. C. Ritchie, and C. P. Larsen. 1996. Analysis of effector mechanisms in murine cardiac allograft rejection. Transpl. Immunol. 4: 46-48.
13. Gareau, A., G. M. Hirsch, T. D. Lee, and B. Nashan. 2009. Contribution of B cells and antibody to cardiac allograft vasculopathy. Transplantation 88: 470-477.
14. Noorchashm, H., A. J. Reed, S. Y. Rostami, R. Mozaffari, G. Zekavat, B. Koeberlein, A. J. Caton, and A. Naji. 2006. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J. Immunol. 177: 7715-7722. (Pubitemid 44846287)
15. Wasowska, B. A., Z. Qian, D. L. Cangello, E. Behrens, K. Van Tran, J. Layton, F. Sanfilippo, and W. M. Baldwin, III. 2001. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 71: 727-736.
16. Nozaki, T., H. Amano, A. Bickerstaff, C. G. Orosz, A. C. Novick, K. Tanabe, and R. L. Fairchild. 2007. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J. Immunol. 179: 5238-5245.
17. João, C., B. M. Ogle, C. Gay-Rabinstein, J. L. Platt, and M. Cascalho. 2004. B cell-dependent TCR diversification. J. Immunol. 172: 4709-4716. (Pubitemid 38456391)
18. Asano, M. S., and R. Ahmed. 1996. CD8 T cell memory in B cell-deficient mice. J. Exp. Med. 183: 2165-2174.
19. Moulin, V., F. Andris, K. Thielemans, C. Maliszewski, J. Urbain, and M. Moser. 2000. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med. 192: 475-482.
20. Crowley, M. T., C. R. Reilly, and D. Lo. 1999. Influence of lymphocytes on the presence and organization of dendritic cell subsets in the spleen. J. Immunol. 163: 4894-4900. (Pubitemid 29501254)
21. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
22. Yazawa, N., Y. Hamaguchi, J. C. Poe, and T. F. Tedder. 2005. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl. Acad. Sci. USA 102: 15178-15183.
23. Tedder, T. F. 2009. CD19: a promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5: 572-577.
24. Hamaguchi, Y., J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174: 4389-4399.
25. DiLillo, D. J., Y. Hamaguchi, Y. Ueda, K. Yang, J. Uchida, K. M. Haas, G. Kelsoe, and T. F. Tedder. 2008. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180: 361-371.
26. Zhou, L.-J., H. M. Smith, T. J. Waldschmidt, R. Schwarting, J. Daley, and T. F. Tedder. 1994. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol. Cell. Biol. 14: 3884-3894.
27. Sato, S., N. Ono, D. A. Steeber, D. S. Pisetsky, and T. F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157: 4371-4378.
28. Sato, S., D. A. Steeber, P. J. Jansen, and T. F. Tedder. 1997. CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. J. Immunol. 158: 4662-4669.
29. Nadler, L. M., K. C. Anderson, G. Marti, M. Bates, E. Park, J. F. Daley, and S. F. Schlossman. 1983. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol. 131: 244-250.
30. Engel, P., L.-J. Zhou, D. C. Ord, S. Sato, B. Koller, and T. F. Tedder. 1995. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3: 39-50.
31. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76: 34-40.
32. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
33. Zola, H., P. J. MacArdle, T. Bradford, H. Weedon, H. Yasui, and Y. Kurosawa. 1991. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol. 69: 411-422.
34. Uchida, J., Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J. A. Oliver, K. Bowen, D. A. Steeber, K. M. Haas, J. C. Poe, and T. F. Tedder. 2004. Mouse CD20 expression and function. Int. Immunol. 16: 119-129.
35. Mannon, R. B., B. L. Kotzin, C. Nataraj, K. Ferri, E. Roper, R. J. Kurlander, and T. M. Coffman. 1998. Downregulation of T cell receptor expression by CD8(+) lymphocytes in kidney allografts. J. Clin. Invest. 101: 2517-2527.
36. Billingham, R. E. 1961. Free skin grafting in mammals. In Transplantation of Tissues and Cells. R. E. Billingham, and W. K. Silvers, eds. The Wistar Institute Press, Philadelphia, p. 1-24.
37. Coffman, T., S. Geier, S. Ibrahim, R. Griffiths, R. Spurney, O. Smithies, B. Koller, and F. Sanfilippo. 1993. Improved renal function in mouse kidney allografts lacking MHC class I antigens. J. Immunol. 151: 425-435. (Pubitemid 23207008)
38. Spurney, R. F., S. Ibrahim, D. Butterly, P. E. Klotman, F. Sanfilippo, and T. M. Coffman. 1994. Leukotrienes in renal transplant rejection in rats. Distinct roles for leukotriene B4 and peptidoleukotrienes in the pathogenesis of allograft injury. J. Immunol. 152: 867-876.
39. Spurney, R. F., P. Ruiz, D. S. Pisetsky, and T. M. Coffman. 1991. Enhanced renal leukotriene production in murine lupus: role of lipoxygenase metabolites. Kidney Int. 39: 95-102.
40. Wijdenes, J., W. C. Vooijs, C. Clément, J. Post, F. Morard, N. Vita, P. Laurent, R. X. Sun, B. Klein, and J. M. Dore. 1996. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol. 94: 318-323.
41. Sanderson, R. D., P. Lalor, and M. Bernfield. 1989. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1: 27-35.
42. Hoyer, B. F., K. Moser, A. E. Hauser, A. Peddinghaus, C. Voigt, D. Eilat, A. Radbruch, F. Hiepe, and R. A. Manz. 2004. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199: 1577-1584.
43. Tedder, T. F., and P. Engel. 1994. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15: 450-454. (Pubitemid 24272191)
44. Robinson, L. A., C. Nataraj, D. W. Thomas, D. N. Howell, R. Griffiths, V. Bautch, D. D. Patel, L. Feng, and T. M. Coffman. 2000. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J. Immunol. 165: 6067-6072.
45. Ehst, B. D., E. Ingulli, and M. K. Jenkins. 2003. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am. J. Transplant. 3: 1355-1362.
46. Epstein, M. M., F. Di Rosa, D. Jankovic, A. Sher, and P. Matzinger. 1995. Successful T cell priming in B cell-deficient mice. J. Exp. Med. 182: 915-922.
47. Mannon, R. B., J. B. Kopp, P. Ruiz, R. Griffiths, M. Bustos, J. L. Platt, P. E. Klotman, and T. M. Coffman. 1999. Chronic rejection of mouse kidney allografts. Kidney Int. 55: 1935-1944.
48. Michaels, P. J., M. C. Fishbein, and R. B. Colvin. 2003. Humoral rejection of human organ transplants. Springer Semin. Immunopathol. 25: 119-140.
49. Bouaziz, J.-D., K. Yanaba, and T. F. Tedder. 2008. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224: 201-214.
50. Wu, G. D., Y. He, N. N. Chai, M. Toyoda, R. Dunn, M. R. Kehry, A. S. Klein, and S. C. Jordan. 2008. Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization. Transpl. Immunol. 19: 178-186.
51. Patselas, T., W. Marchman, D. Araneda, J. Thomas, and F. Thomas. 1992. Normal rejection of xenografts by strongly deficient B-cell animals (X-linked immunodeficient mice). Transplant. Proc. 24: 494.
52. Cerny, A., H. Ramseier, H. Bazin, and R. M. Zinkernagel. 1988. Unimpaired first-set and second-set skin graft rejection in agammaglobulinemic mice. Transplantation 45: 1111-1113.
53. Winn, H. J., C. A. Baldamus, S. V. Jooste, and P. S. Russell. 1973. Acute destruction by humoral antibody of rat skin grafted to mice. J. Exp. Med. 137: 893-910.
54. Jooste, S. V., and H. J. Winn. 1975. Acute destruction of rat skin grafts by alloantisera. J. Immunol. 114: 933-938.
55. Russell, P. S., C. M. Chase, H. J. Winn, and R. B. Colvin. 1994. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J. Immunol. 152: 5135-5141.
56. Nozaki, T., J. M. Rosenblum, D. Ishii, K. Tanabe, and R. L. Fairchild. 2008. CD4 T cell-mediated rejection of cardiac allografts in B cell-deficient mice. J. Immunol. 181: 5257-5263.
57. Rifle, G., C. Mousson, L. Martin, F. Guignier, and K. Hajji. 2005. Donor-specific antibodies in allograft rejection: clinical and experimental data. Transplantation 79(3, Suppl): S14-S18. (Pubitemid 40293566)
58. Vieira, C. A., A. Agarwal, B. K. Book, R. A. Sidner, C. M. Bearden, H. M. Gebel, A. L. Roggero, N. S. Fineberg, T. Taber, M. A. Kraus, and M. D. Pescovitz. 2004. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77: 542-548.
59. Claas, F. H., and I. I. Doxiadis. 2009. Management of the highly sensitized patient. Curr. Opin. Immunol. 21: 569-572.
60. Singh, N., J. Pirsch, and M. Samaniego. 2009. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant. Rev. (Orlando) 23: 34-46.
61. Vo, A. A., M. Lukovsky, M. Toyoda, J. Wang, N. L. Reinsmoen, C. H. Lai, A. Peng, R. Villicana, and S. C. Jordan. 2008. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359: 242-251.
62. Stegall, M. D., J. Gloor, J. L. Winters, S. B. Moore, and S. Degoey. 2006. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. 6: 346-351.
63. Garrett, H. E., Jr., D. Duvall-Seaman, B. Helsley, and K. Groshart. 2005. Treatment of vascular rejection with rituximab in cardiac transplantation. J. Heart Lung Transplant. 24: 1337-1342. (Pubitemid 41247819)
64. Becker, Y. T., B. N. Becker, J. D. Pirsch, and H. W. Sollinger. 2004. Rituximab as treatment for refractory kidney transplant rejection. Am. J. Transplant. 4: 996-1001.
65. Clatworthy, M. R., C. J. Watson, G. Plotnek, V. Bardsley, A. N. Chaudhry, J. A. Bradley, and K. G. Smith. 2009. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 360: 2683-2685.